FDA Pulls Ranitidine Drugs (Zantac) Off Market Because of Cancer Risk
Effective April 1, 2020 the Food and Drug Administration requested the removal of ranitidine products (brand name Zantac) from the market. These popular over-the-counter products have been used as an antacid for reflux and other intestinal conditions for decades. The FDA on April 1, 2020 said:
“[I]t is requesting manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine drugs from the market immediately.
This is the latest step in an ongoing investigation of a contaminant known as N-Nitrosodimethylamine (NDMA) in ranitidine medications
(commonly known by the brand name Zantac).”